Description

The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the onset of lifestyle diseases such as diabetes. The use of advanced artificial intelligence (AI) has enabled the predictive capabilities of these apps by providing predictive insights on physiological markers, including the prediction of blood glucose levels. Conventional prescription medications for type 2 diabetes (T2D) comprise oral drugs. Still, there is a rising use of insulin for T2D management, especially for patients who are unable to manage blood sugar levels with oral medicines. Insulin continues to be a mainstay for treating T1D patients, with continuous advances in insulin delivery platforms.

Hybrid closed-loop systems or artificial pancreas are fast emerging as a preferred treatment option for optimally managing T1D. These systems typically comprise a CGM, an insulin pump, and an advanced algorithm that facilitates cross talk between the monitoring and delivery platforms for managing blood sugar levels continuously. The rising use of wearable monitoring devices connected through smartphone apps has enabled several app-based personalized recommendations and actionable predictive insights for improved diabetes management, leading to digital therapeutics development. This research provides insights into advancements in CGMs, insulin delivery technologies, and artificial pancreas. The study also analyzes funding, emerging digital diabetes care technologies, and partnerships shaping the future of global diabetes care.

The study answers the following questions:
What are the key technological advancements in CGM devices and insulin delivery platforms?
Who are the key innovators across device-based diabetes care platforms?
How are funding and partnership trends likely to impact the diabetes care device industry?
What are the emerging trends for digital diabetes care?
What are the growth opportunities for digital diabetes management?